Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT02679261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02679261
Other papers using this trial's data
  • Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial Circulation, 2024-06-18 DOI, PubMed 38804148

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02679261. Randomized; quadruple masking; primary purpose treatment. Start 2016-06 (actual); primary completion 2021-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve
Acronym
BICATOR
Condition
Bicuspid Aortic Valve
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Placebo
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute (class: other)

Record details

Record id
cardio:ct-nct02679261
Content hash
77ede48e2c9058792f9582c2606c6236a74962e4fbd901f119779bd7aeb095e1